195 related articles for article (PubMed ID: 33464558)
1. Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies.
Ansari AS; Amir Z; Williams GS
Ophthalmol Ther; 2021 Mar; 10(1):193-200. PubMed ID: 33464558
[TBL] [Abstract][Full Text] [Related]
2. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S
Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770
[TBL] [Abstract][Full Text] [Related]
3. Fluocinolone acetonide intravitreal implant (Retisert
Leinonen S; Immonen I; Kotaniemi K
Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome.
Marques JH; Abreu AC; Silva N; Meireles A; Pessoa B; Melo Beirão J
Int Med Case Rep J; 2021; 14():127-132. PubMed ID: 33664598
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results.
Chronopoulos A; Chronopoulos P; Hattenbach LO; Ashurov A; Schutz JS; Pfeiffer N; Korb C
Eur J Ophthalmol; 2022 Sep; ():11206721221124688. PubMed ID: 36062617
[TBL] [Abstract][Full Text] [Related]
6. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN
Bodaghi B; Nguyen QD; Jaffe G; Khoramnia R; Pavesio C
J Ophthalmic Inflamm Infect; 2020 Nov; 10(1):32. PubMed ID: 33251553
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair.
Alfaqawi F; Sarmad A; Ayesh K; Mitra A; Sharma A
Turk J Ophthalmol; 2018 Jun; 48(3):155-157. PubMed ID: 29988755
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre.
Pockar S; Leal I; Chhabra R; Jones NP; Steeples LR
Ocul Immunol Inflamm; 2023 Oct; 31(8):1572-1578. PubMed ID: 34124978
[TBL] [Abstract][Full Text] [Related]
9. Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren's syndrome-related keratopathy: a case report.
Wasielica-Poslednik J; Pfeiffer N; Gericke A
J Med Case Rep; 2019 Jan; 13(1):21. PubMed ID: 30674351
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN
Mushtaq Y; Mushtaq MM; Gatzioufas Z; Ripa M; Motta L; Panos GD
Drug Des Devel Ther; 2023; 17():961-975. PubMed ID: 37020801
[TBL] [Abstract][Full Text] [Related]
11. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®).
Coelho J; Pessoa B; Meireles A
Ther Adv Ophthalmol; 2019; 11():2515841418820755. PubMed ID: 30643869
[TBL] [Abstract][Full Text] [Related]
12. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
13. Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.
Drugs R D; 2005; 6(2):116-9. PubMed ID: 15777105
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis.
Pichi F; Nucci P; Baynes K; Lowder CY; Srivastava SK
Int Ophthalmol; 2017 Feb; 37(1):221-228. PubMed ID: 27221263
[TBL] [Abstract][Full Text] [Related]
15. Fluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia.
Cachero Rodríguez JM; Artaraz J; Imaz N; Fonollosa A
J Ophthalmic Inflamm Infect; 2024 May; 14(1):19. PubMed ID: 38700565
[TBL] [Abstract][Full Text] [Related]
16. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema.
Weber LF; Marx S; Auffarth GU; Scheuerle AF; Tandogan T; Mayer C; Khoramnia R
J Ophthalmic Inflamm Infect; 2019 Jan; 9(1):3. PubMed ID: 30694420
[TBL] [Abstract][Full Text] [Related]
17. Fluocinolone acetonide implant (Iluvien®) for macular edema associated with retinitis pigmentosa: A case report.
Jomaa E; Delyfer MN; Korobelnik JF
Eur J Ophthalmol; 2023 Nov; 33(6):NP96-NP99. PubMed ID: 36474351
[TBL] [Abstract][Full Text] [Related]
18. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN
Carneiro A; Meireles A; Castro Sousa JP; Teixeira C
Ther Adv Ophthalmol; 2020; 12():2515841420917768. PubMed ID: 32548568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
